379 related articles for article (PubMed ID: 29223870)
1. Validation of an algorithm to detect severe MS relapses in administrative health databases.
Marriott JJ; Chen H; Fransoo R; Marrie RA
Mult Scler Relat Disord; 2018 Jan; 19():134-139. PubMed ID: 29223870
[TBL] [Abstract][Full Text] [Related]
2. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
[TBL] [Abstract][Full Text] [Related]
3. Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.
Colais P; Agabiti N; Davoli M; Buttari F; Centonze D; De Fino C; Di Folco M; Filippini G; Francia A; Galgani S; Gasperini C; Giuliani M; Mirabella M; Nociti V; Pozzilli C; Bargagli A;
Neuroepidemiology; 2017; 48(3-4):171-178. PubMed ID: 28793295
[TBL] [Abstract][Full Text] [Related]
4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
5. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
7. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
Lage MJ; Carroll CA; Fairman KA
J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
[TBL] [Abstract][Full Text] [Related]
8. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort.
Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L
Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141
[TBL] [Abstract][Full Text] [Related]
9. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
Iaffaldano P; Lucisano G; Guerra T; Patti F; Cocco E; De Luca G; Brescia Morra V; Pozzilli C; Zaffaroni M; Ferraro D; Gasperini C; Salemi G; Bergamaschi R; Lus G; Inglese M; Romano S; Bellantonio P; Di Monte E; Maniscalco GT; Conte A; Lugaresi A; Vianello M; Torri Clerici VLA; Di Sapio A; Pesci I; Granella F; Totaro R; Marfia GA; Danni MC; Cavalla P; Valentino P; Aguglia U; Montepietra S; Ferraro E; Protti A; Spitaleri D; Avolio C; De Riz M; Maimone D; Cavaletti G; Gazzola P; Tedeschi G; Sessa M; Rovaris M; Di Palma F; Gatto M; Cargnelutti D; De Robertis F; Logullo FO; Rini A; Meucci G; Ardito B; Banfi P; Nasuelli D; Paolicelli D; Rocca MA; Portaccio E; Chisari CG; Fenu G; Onofrj M; Carotenuto A; Ruggieri S; Tortorella C; Ragonese P; Nica M; Amato MP; Filippi M; Trojano M;
J Neurol; 2024 Mar; 271(3):1150-1159. PubMed ID: 38135850
[TBL] [Abstract][Full Text] [Related]
11. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Burton JM; O'Connor PW; Hohol M; Beyene J
Cochrane Database Syst Rev; 2009 Jul; (3):CD006921. PubMed ID: 19588409
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
13. Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis.
Capkun G; Lahoz R; Verdun E; Song X; Chen W; Korn JR; Dahlke F; Freitas R; Fraeman K; Simeone J; Johnson BH; Nordstrom B
Curr Med Res Opin; 2015 May; 31(5):1029-39. PubMed ID: 25661016
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
17. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
[TBL] [Abstract][Full Text] [Related]
18. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
19. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
[TBL] [Abstract][Full Text] [Related]
20. Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data.
Van Le H; Le Truong CT; Kamauu AWC; Holmén J; Fillmore C; Kobayashi MG; Martin C; Sabidó M; Wong SL
Value Health; 2019 Jan; 22(1):77-84. PubMed ID: 30661637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
